Displaying 1 - 20 of 34 tests
B-ALL Add-On Flow Panel
Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD3, cCD22, cCD79a, CD10, CD19, CD34, CD45, cMPO, and nTdt (9 markers).
Flow Cytometry
B-ALL MRD Flow Panel
Available as global test only. Markers are CD3, CD9, CD10, CD13/CD33, CD19, CD20, CD34, CD38, CD45, CD58, CD71, and Syto16 (13 markers; Syto16 is not reported). This panel can detect MRD at the 0.01% level.
Flow Cytometry
B-Cell Gene Rearrangement
Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of
Molecular
B-Cell Lymphoma Follow-Up Flow Panel
Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are
Flow Cytometry
B72.3
This monoclonal antibody (B72.3) to tumor-associated glycoprotein recognizes a tumor-associated oncofetal antigen (TAG-72) expressed by a wide variety of human adenocarcinomas. This antigen is expressed by most invasive ductal breast, colonic, pancreatic, gastric, esophageal, lung, ovarian and
Immunohistochemistry (IHC)
BAP1
BAP1 IHC stain is a tool for detection of BAP1 mutations with subsequent inactivation. Loss of BAP1 by IHC is 100% specific for malignant mesothelioma in the context of mesothelioma vs. mesothelial hyperplasia. Loss of BAP1 may be seen in other neoplasms.
Immunohistochemistry (IHC)
BCA-225
This antibody recognizes a human breast carcinoma associated glycoprotein BCA-225 (220-225kD). This protein differs in size and distribution from other breast carcinoma antigens. It does not react with benign or malignant gastrointestinal tissues. It can be used to identify skin carcinomas with
Immunohistochemistry (IHC)
BCL1 Translocation, t(11;14)
Real-time PCR for quantitative detection of t(11;14) BCL1/IgH rearrangements. Analytical sensitivity is approximately 1 tumor cell in 1000 normal cells. Positive results are reported as a ratio between quantities of (11;14) DNA and a normal control gene. This translocation is also known as CCND1/IgH
Molecular
BCL1/Cyclin D1
BCL1/Cyclin D1 is a nuclear protein detectable in formalin-fixed, paraffin-embedded (FFPE) sections and is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator possibly by
Immunohistochemistry (IHC)
BCL10
BCL-10 is an N-terminal CARD (Caspase Recruitment Domain) containing protein that is involved in the adaptive immune response. It is also a substrate for MALT1. Mutations in the gene can lead to lymphoma, mucosa-associated lymphoid type. It is useful in the assessment of pancreatic tumors to
Immunohistochemistry (IHC)
BCL2
B-cell lymphoma 2 (BCL2) was the first of the translocation-associated proteins to be identified in lymphoma. Most cases of follicular lymphoma have a [t(14;18)] translocation, resulting in BCL2 overexpression. Overexpression of BCL2 in activated diffuse B-cell lymphoma may predict disease
Immunohistochemistry (IHC)
BCL2
Probes: BCL2 (18q21) Disease(s) : B-cell lymphoma, non-Hodgkin lympoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL)
FISH
BCL2 Translocation, t(14;18)
PCR and fragment analysis for quantitative detection of IGH-BCL2 translocations associated with 70-80% of follicular lymphoma and approximately 20% of diffuse large B-cell lymphoma. Translocations involving the major (MBR), minor (MCR), and 3' MBR sub-cluster regions of BCL2 are analyzed. Positive
Molecular
BCL6
BCL6 antibody stains the germinal center cells in lymphoid follicles, the follicular cells and interfollicular cells in follicular lymphoma, a subset of diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of Reed-Sternberg cells in nodular lymphocyte predominant Hodgkin
Immunohistochemistry (IHC)
BCL6 (3q27)
Probes: BCL6 (3q27) Disease(s): Diffuse large B-cell lymphoma, NHL
FISH
BCR-ABL1 Non-Standard p230
Real-time RT-PCR for detection of t(9;22) BCR-ABL1 fusion transcripts that result in p230 fusion proteins. Analytical sensitivity is 1 tumor cell in 100,000 normal cells. BCR-ABL1 Standard p210, p190 may be ordered as a stand-alone test.
Molecular
BCR-ABL1 Standard p210, p190
Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (E13, E14) or minor p190 (E1) fusion proteins with option to add p230 detection (micro or atypical variant). p230 testing may be ordered as a stand-alone test. For p210 and p190, analytical
Molecular
BCR/ABL1 t(9;22)
Probes: ABL1 (9q34); ASS1 (9q34; BCR (22q11.2) Disease(s): CML, ALL, MPN Note: For suspected ALL, STAT processing is available by request. Note STAT along with MD contact name and phone number to receive STAT results.
FISH
BerEP4
Ber-EP4 recognizes two glycoproteins of 34 and 49 kDa present on the surface and the cytoplasm of all epithelial cells except the superficial layers of squamous epithelial, hepatocytes and parietal cells. It does not label mesothelial cells and rarely marks mesotheliomas. It shows a broad spectrum
Immunohistochemistry (IHC)
Beta Catenin
Beta-catenin is an important regulator of cell–cell adhesion and embryogenesis. Mutations of beta-catenin could lead to some human cancers. Normal cells show membrane staining for beta-catenin, while cytoplasmic and/or nuclear staining is abnormal. Dysregulation of beta-catenin occurs in Gardner
Immunohistochemistry (IHC)